标题
Multi-Target Approaches in Metabolic Syndrome
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-03-12
DOI
10.3389/fphar.2020.554961
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119
- (2020) Gang Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis
- (2020) Donatella Chianelli et al. JOURNAL OF MEDICINAL CHEMISTRY
- Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments
- (2020) Konstantinos A. Toulis et al. DRUGS
- Dual soluble epoxide hydrolase inhibitor/PPAR-γ agonist attenuates renal fibrosis
- (2020) Anna Stavniichuk et al. PROSTAGLANDINS & OTHER LIPID MEDIATORS
- Synthesis and evaluation of novel fused pyrimidine derivatives as GPR119 agonists
- (2019) Yuanying Fang et al. BIOORGANIC CHEMISTRY
- Efficacy and Safety of Dual Blockade of the Renin–Angiotensin–Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis
- (2019) Yanhuan Feng et al. American Journal of Cardiovascular Drugs
- A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice
- (2019) Md. Abdul Hye Khan et al. BIOCHEMICAL PHARMACOLOGY
- Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome
- (2019) Alessandra Ammazzalorso et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: An open-label, randomized clinical trial
- (2019) Mitsuhide Naruse et al. PLoS One
- Design and synthesis of tetrahydropyridopyrimidine derivatives as dual GPR119 and DPP-4 modulators
- (2019) Yuanying Fang et al. BIOORGANIC CHEMISTRY
- Telmisartan Improves Insulin Resistance
- (2018) Yan Wang et al. AMERICAN JOURNAL OF THERAPEUTICS
- A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes
- (2018) Md Abdul Hye Khan et al. DIABETOLOGIA
- Semaglutide: First Global Approval
- (2018) Sohita Dhillon DRUGS
- The safety of gliptins : updated data in 2018
- (2018) André Jacques Scheen Expert Opinion On Drug Safety
- Update on FXR Biology: Promising Therapeutic Target?
- (2018) Chang Han INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Progress and challenges of selective Farnesoid X Receptor modulation
- (2018) Vittoria Massafra et al. PHARMACOLOGY & THERAPEUTICS
- Polypharmacy among patients with diabetes: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia
- (2018) Monira Alwhaibi et al. BMJ Open
- Discovery of the bifunctional modulator of angiotensin II type 1 receptor (AT1R) and PPARγ derived from the AT1R antagonist, Fimasartan
- (2018) Wonken Choung et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
- (2018) Ewgenij Proschak et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases
- (2018) Stella Bernardi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Orally Active Epoxyeicosatrienoic Acid Analogs
- (2017) William B. Campbell et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Nutrient-sensing nuclear receptors PPARα and FXR control liver energy balance
- (2017) Geoffrey A. Preidis et al. JOURNAL OF CLINICAL INVESTIGATION
- Current and future pharmacological therapies for NAFLD/NASH
- (2017) Yoshio Sumida et al. JOURNAL OF GASTROENTEROLOGY
- A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis
- (2017) Jurema Schmidt et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2017) David C. Tully et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
- (2017) Mukul R. Jain et al. LIVER INTERNATIONAL
- Therapies in non-alcoholic steatohepatitis (NASH)
- (2017) Abdul M. Oseini et al. LIVER INTERNATIONAL
- Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acids
- (2017) Amy A. Rand et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphatase activity of soluble epoxide hydrolase
- (2017) Jan Kramer et al. PROSTAGLANDINS & OTHER LIPID MEDIATORS
- The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo
- (2017) Yi Huan et al. Scientific Reports
- Nuclear receptors and nonalcoholic fatty liver disease 1 1This article is part of a Special Issue entitled: Xenobiotic nuclear receptors: New Tricks for An Old Dog, edited by Dr. Wen Xie.
- (2016) Matthew C. Cave et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents
- (2016) Gang Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Investigational glucagon-like peptide-1 agonists for the treatment of obesity
- (2016) Brian Tomlinson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Obesity: Current Treatment and Future Horizons
- (2016) Ziad Omran MINI-REVIEWS IN MEDICINAL CHEMISTRY
- The soluble epoxide hydrolase determines cholesterol homeostasis by regulating AMPK and SREBP activity
- (2016) Nicole Mangels et al. PROSTAGLANDINS & OTHER LIPID MEDIATORS
- Reply to Letter to the Editor “Polypharmacy in elderly people with diabetes admitted to hospital”
- (2015) Marianna Noale et al. ACTA DIABETOLOGICA
- Anthranilic acid derivatives as nuclear receptor modulators—Development of novel PPAR selective and dual PPAR/FXR ligands
- (2015) Daniel Merk et al. BIOORGANIC & MEDICINAL CHEMISTRY
- FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease
- (2015) Rotonya M. Carr et al. Current Atherosclerosis Reports
- Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
- (2015) Mil.osz Regulski et al. CURRENT PHARMACEUTICAL DESIGN
- G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges
- (2015) Kurt Ritter et al. JOURNAL OF MEDICINAL CHEMISTRY
- N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators
- (2015) René Blöcher et al. JOURNAL OF MEDICINAL CHEMISTRY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Antidiabetic potential of a novel dual-target activator of glucokinase and peroxisome proliferator activated receptor-γ
- (2015) Lei Lei et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Bile acids, obesity, and the metabolic syndrome
- (2014) Huijuan Ma et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR)
- (2014) Daniel Merk et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPARγ agonists
- (2014) Yann Lamotte et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design, Synthesis, and Activity Evaluation of GK/PPARγ Dual-Target-Directed Ligands as Hypoglycemic Agents
- (2014) Jianxun Lu et al. ChemMedChem
- Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes
- (2014) Nathalie Esser et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Discovery of novel urea derivatives as dual-target hypoglycemic agents that activate glucokinase and PPARγ
- (2014) Yongqiang Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- A review of gliptins for 2014
- (2014) André J Scheen EXPERT OPINION ON PHARMACOTHERAPY
- Novel MCH1receptor antagonists: a patent review
- (2014) Anders Johansson et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Extending the Structure–Activity Relationship of Anthranilic Acid Derivatives As Farnesoid X Receptor Modulators: Development of a Highly Potent Partial Farnesoid X Receptor Agonist
- (2014) Daniel Merk et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cardiovascular Disease-Related Parameters and Oxidative Stress in SHROB Rats, a Model for Metabolic Syndrome
- (2014) Eunice Molinar-Toribio et al. PLoS One
- The Cytochrome P450 Epoxygenase Pathway Regulates the Hepatic Inflammatory Response in Fatty Liver Disease
- (2014) Robert N. Schuck et al. PLoS One
- Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis
- (2014) G. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Integrated physiology and systems biology of PPARα
- (2014) Sander Kersten Molecular Metabolism
- A comparative study on the effectiveness of losartan/hydrochlorothiazide and telmisartan/hydrochlorothiazide in patients with hypertension
- (2013) Toshihiro Hamada et al. CLINICAL AND EXPERIMENTAL HYPERTENSION
- Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats
- (2013) John D Imig et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Mechanisms of Diabetic Complications
- (2013) Josephine M. Forbes et al. PHYSIOLOGICAL REVIEWS
- Stimulating β-Cell Regeneration by Combining a GPR119 Agonist with a DPP-IV Inhibitor
- (2013) Ansarullah et al. PLoS One
- Impact of Soluble Epoxide Hydrolase and Epoxyeicosanoids on Human Health
- (2012) Christophe Morisseau et al. Annual Review of Pharmacology and Toxicology
- Role of epoxide hydrolases in lipid metabolism
- (2012) Christophe Morisseau BIOCHIMIE
- Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists
- (2012) Tae Woo Kim et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Melanin concentrating hormone receptor 1 (MCHR1) antagonists—Still a viable approach for obesity treatment?
- (2012) Thomas Högberg et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- An example of designed multiple ligands spanning protein classes: Dual MCH-1R antagonists/DPPIV inhibitors
- (2012) William T. Gattrell et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ
- (2012) Agustin Casimiro-Garcia et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Nuclear Receptors Reverse McGarry's Vicious Cycle to Insulin Resistance
- (2012) David D. Moore Cell Metabolism
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
- (2012) Naga Chalasani et al. HEPATOLOGY
- A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARγ to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction
- (2012) Dan-yan Xu et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction
- (2012) Andrew R. Kompa et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Design and Synthesis of Dual Modulators of Soluble Epoxide Hydrolase and Peroxisome Proliferator-Activated Receptors
- (2012) Estel.la Buscató et al. JOURNAL OF MEDICINAL CHEMISTRY
- GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function
- (2012) Shinji Odori et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Inhibition of Soluble Epoxide Hydrolase Attenuates High-Fat-Diet–Induced Hepatic Steatosis by Reduced Systemic Inflammatory Status in Mice
- (2012) Yan Liu et al. PLoS One
- Attenuation of Renovascular Damage in Zucker Diabetic Fatty Rat by NWT-03, an Egg Protein Hydrolysate with ACE- and DPP4-Inhibitory Activity
- (2012) Yumei Wang et al. PLoS One
- GPR119 as a fat sensor
- (2012) Harald S. Hansen et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2012) Yoshihisa Takahashi WORLD JOURNAL OF GASTROENTEROLOGY
- Discovery of a novel series of melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity
- (2011) Jeffrey T. Mihalic et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist
- (2011) Mairi Sime et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Overcoming Obstacles in Risk Factor Management in Type 2 Diabetes Mellitus
- (2011) Yehuda Handelsman et al. Journal of Clinical Hypertension
- Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice
- (2011) Dipak Panigrahy et al. JOURNAL OF CLINICAL INVESTIGATION
- Discovery of a Series of Imidazo[4,5-b]pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-γ
- (2011) Agustin Casimiro-Garcia et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Inhibitors of Soluble Epoxide Hydrolase: A Target with Multiple Potential Therapeutic Indications
- (2011) Hong C. Shen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists—A perspective
- (2010) Prashant Naik et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Pioglitazone: side effect and safety profile
- (2010) Priya Shah et al. Expert Opinion On Drug Safety
- New central targets for the treatment of obesity
- (2009) Bruce J. Sargent et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Global estimates of the prevalence of diabetes for 2010 and 2030
- (2009) J.E. Shaw et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases
- (2009) John D. Imig et al. NATURE REVIEWS DRUG DISCOVERY
- The Metabolic Syndrome
- (2009) Matthew V. Potenza et al. NUTRITION IN CLINICAL PRACTICE
- Fat and Beyond: The Diverse Biology of PPARγ
- (2008) Peter Tontonoz et al. Annual Review of Biochemistry
- The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality
- (2008) Panagiotis C. Stafylas et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Arachidonic acid cytochrome P450 epoxygenase pathway
- (2008) Arthur A. Spector JOURNAL OF LIPID RESEARCH
- Efficacy and safety of the weight-loss drug rimonabant
- (2008) Jean-Pierre Després et al. LANCET
- Transcriptional regulation of the human soluble epoxide hydrolase gene EPHX2
- (2007) Hiromasa Tanaka et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now